Singh, Kamalinder and Pople, Pallavi (2011) Safer Than Safe: Lipid Nanoparticulate Encapsulation of Tacrolimus with Enhanced Targeting and Improved Safety for Atopic Dermatitis. Journal of Biomedical Nanotechnology, 7 (1). pp. 40-41. ISSN 15507033
Full text not available from this repository.
Official URL: http://dx.doi.org/10.1166/jbn.2011.1191
Atopic dermatitis (AD) is a skin disorder having significant impact worldwide, characterized by itchy, erythematous and intensely pruritic rash with periods of remission. Tacrolimus is the drug-of-choice in treatment of many immune mediated dermatoses including AD. Despite being effective, most common adverse events of tacrolimus are burning sensation and pruritus at the application site prompting for development of novel carrier that could effectively target tacrolimus to site-of-action without producing undesirable toxic-effects. Tacrolimus loaded lipid nanoparticles (T-LN) were developed and evaluated comparatively for enhanced targeting potential to site of action and improved safety with commercially available ointment product, Protopic® as reference. T-LN was successfully developed by high pressure homogenization technique. Significantly higher drug release and skin permeating properties were observed for T-LN as compared to reference. T-LN suppressed inflammatory response in vivo by 3.5 times more efficiently than reference, demonstrating its improved efficacy. Entrapment of tacrolimus in lipid nanoparticles avoided direct contact of drug with skin; alleviating drug related local side effects.
|Schools:||Faculty of Clinical & Biomedical Sciences > School of Pharmacy and Biomedical Sciences|
|Deposited By:||Paul Harrison|
|Deposited On:||20 Jul 2015 10:54|
|Last Modified:||09 Aug 2016 15:22|
Downloads per month over past year
Downloads for past 30 days
Repository Staff Only: item control page